By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Alzheimer's Institute of America, Inc. v. Avid Radiopharmaceuticals et al.
2:10-cv-06908; filed November 24, 2010 in the Eastern District of Pennsylvania
• Plaintiff: Alzheimer's Institute of America, Inc.
• Defendants: Avid Radiopharmaceuticals; The Trustees of the University of Pennsylvania
Infringement of U.S. Patent Nos. 5,455,169 ("Nucleic Acids for Diagnosing and Modeling Alzheimer's Disease," issued October 3, 1995) and 7,538,258 ("Transgenic Mouse Expressing an APP 670/671 Mutation," issued May 26, 2009) based on defendants' use of Alzheimer's Institute's Alzheimer's Disease-related technology, including conducting research involving the use of, manufacturing and selling detection systems for, and/or manufacturing and selling products containing the Swedish mutation. View the complaint here.
Life Technologies Corp. et al. v. Genmark Diagnostics, Inc.
3:10-cv-02392; filed November 19, 2010 in the Southern District of California
• Plaintiffs: Life Technologies Corp.; Applied Biosystems, LLC
• Defendant: Genmark Diagnostics, Inc.
Infringement of U.S. Patent No. 6,514,699 ("Multiplex Polynucleotide Capture Methods and Compositions," issued February 4, 2003) based on Genmark's manufacture, offer for sale, and of its eSensor® system, cartridges and reagents for nucleic acid analysis. View the complaint here.
Cancer Research Technology Ltd. et al. v. Accord Healthcare, Inc.
3:10-cv-06096; filed November 19, 2010 in the District Court of New Jersey
• Plaintiffs: Cancer Research Technology Ltd.; Schering Corp.
• Defendant: Accord Healthcare, Inc.
Infringement of U.S. Patent No. 5,260,291 ("Tetrazine Derivatives," issued November 9, 1993) following a Paragraph IV certification as part of Accord's filing of an ANDA to manufacture a generic version of plaintiffs' Temodar® (temozolomide, used to treat brain tumors). View the complaint here.
Regeneron Pharmaceuticals, Inc. v. Genentech, Inc.
7:10-cv-08779; filed November 19, 2010 in the Southern District of New York
Declaratory judgment of non-infringement and/or invalidity of U.S. Patent Nos. 5,952,199 ("Chimeric Receptors as Inhibitors of Vascular Endothelial Growth Factor Activity, and Processes for Their Production," issued September 14, 1999), 6,100,071 ("Receptors as Novel Inhibitors of Vascular Endothelial Growth Factor Activity and Processes for Their Production," issued August 8, 2000), 6,383,486 ("Inhibitors of Vascular Endothelial Growth Factor Activity, Their Uses and Processes for Their Production," issued May 7, 2002), 6,897,294 (same title, issued May 24, 2005), and 7,771,721 ("Methods for Using Chimeric Vascular Endothelial Growth Factor Receptor Proteins," issued August 10, 2010) based on Regeneron's planned Biological License Application for its VEGF Trap for treating we age-related macular degeneration. View the complaint here.
Ortho-Mcneil-Janssen Pharmaceuticals, Inc. v. Mylan Inc. et al.
2:10-cv-06018; filed November 12, 2010 in the District Court of New Jersey
• Plaintiff: Ortho-Mcneil-Janssen Pharmaceuticals, Inc.
• Defendants: Mylan Inc.; Mylan Pharmaceuticals Inc.; Famy Care Ltd.
Infringement of U.S. Patent No. 6,214,815 ("Triphasic Oral Contraceptive," issued April 10, 2001) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Ortho-McNeil's Ortho Tri-Cyclen Lo® (norgestimate and ethinyl estradiol, used for oral contraception). View the complaint here.
Comments